A new generation of vaccines within animal health
Intervacc AB is a Swedish company active in the biotechnology sector. We develop new vaccines based on fusions of recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile.
Together with our two subsidiaries Nordvacc Läkemedel and the Mybac-Vettech Laboratory, we strive to strengthen animal health and welfare. Here you can find more about the Group’s products and services our project portfolio for a new generation of vaccines against bacterial infections.
- Intervacc’s subsidiary company Nordvacc have over 30 years’ experience in the veterinary vaccines market, serving the Nordic, Dutch and Baltic markets with more than 200 million doses sold
- The technology platform is based on research from the Karolinska Institute and the Swedish University of Agricultural Sciences